BioCentury
ARTICLE | Company News

Hyperion Therapeutics Inc, Clal, Weizmann Institute of Science deal

March 2, 2015 8:00 AM UTC

Hyperion and Clal settled an ongoing dispute related to the development of DiaPep277 and partnered to complete the Phase III DIA-AID 2 trial of the compound to treat Type I diabetes. Hyperion is responsible for completing the study with DiaPep277, which was originally developed by the Weizmann Institute. A steering committee consisting of members from all three parties will oversee the trial. Hyperion discontinued development of DiaPep277 and alleged research misconduct during the DIA-AID 1 and 2 trials by employees of its Andromeda Biotech Ltd. subsidiary, which it had acquired from Clal in 2014. DiaPep277 is a peptide composed of 24 amino acids derived from the sequence of heat shock protein 60 (Hsp60) (see BioCentury, Sept. 15, 2014). ...